Research programme: non-nucleoside reverse transcriptase inhibitors - Medivir AB
Alternative Names: MIV-170; NNRTI research programme - Medivir AB; Non-nucleoside reverse transcriptase inhibitors research programme - Medivir ABLatest Information Update: 09 Jul 2007
At a glance
- Originator Medivir AB
- Class
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 06 Jul 2007 Bristol-Myers Squibb terminates its licence for MIV 170
- 13 Sep 2006 MIV 170 has been licensed to Bristol-Myers Squibb worldwide for the treatment of HIV-1 infections in adult patients
- 28 Dec 2005 This programme is still in active development